Media coverage about Galmed Pharmaceuticals (NASDAQ:GLMD) has been trending somewhat positive on Thursday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Galmed Pharmaceuticals earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.5044295777756 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the media stories that may have effected Accern’s analysis:
- Galmed Pharmaceuticals to Provide Corporate Update at the LEERINK Partners 7th Annual Global Healthcare Conference (finance.yahoo.com)
- Galmed Granted “Preferred Technological Enterprise” Status Which may Provide the Company With Significant Financial Benefits (finance.yahoo.com)
- Zacks: Analysts Expect Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $280,000.00 (americanbankingnews.com)
- -$0.23 Earnings Per Share Expected for Galmed Pharmaceuticals Ltd (GLMD) This Quarter (americanbankingnews.com)
Galmed Pharmaceuticals (GLMD) traded down $0.39 during mid-day trading on Thursday, reaching $9.47. The company’s stock had a trading volume of 36,774 shares, compared to its average volume of 56,412. The firm has a market cap of $124.66, a P/E ratio of -8.53 and a beta of 2.42. Galmed Pharmaceuticals has a fifty-two week low of $3.90 and a fifty-two week high of $12.22.
A number of brokerages recently commented on GLMD. ValuEngine raised Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research lowered Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. Maxim Group set a $14.00 target price on Galmed Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Roth Capital initiated coverage on Galmed Pharmaceuticals in a research report on Wednesday, November 15th. They issued a “buy” rating and a $32.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Galmed Pharmaceuticals in a research note on Friday, November 10th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $19.20.
ILLEGAL ACTIVITY WARNING: “Galmed Pharmaceuticals (GLMD) Getting Somewhat Favorable Media Coverage, Accern Reports” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://sportsperspectives.com/2018/02/08/galmed-pharmaceuticals-glmd-getting-somewhat-favorable-media-coverage-accern-reports.html.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.